The nocebo effect and patient perceptions of biosimilars in inflammatory bowel disease

  • David Pineles
  • Lisa Malter
  • Peter S. Liang
  • Amy Arsuaga
  • Brian Bosworth
  • David P. Hudesman
  • Shannon Chang
Letter to the Editor


  1. 1.
    Boone NW, Liu L, Romberg-camps MJ et al (2018) The nocebo effect challenges the non-medical infliximab switch in practice. Eur J Clin Pharmacol 74(5):655–661CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Jacobs I, Singh E, Sewell KL, Al-Sabbagh A, Shane LG (2016) Patient attitudes and understanding about biosimilars: an international cross-sectional survey. Patient Prefer Adherence 10:937–948CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    van Overbeeke E, de Beleyr B, de Hoon J, Westhovens R, Huys I (2017) Perception of originator biologics and biosimilars: a survey among Belgian rheumatoid arthritis patients and rheumatologists. BioDrugs 31(5):447–459CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of MedicineNYU Langone HealthNew YorkUSA
  2. 2.Division of GastroenterologyBellevue HospitalNew YorkUSA
  3. 3.Division of Gastroenterology, VA New York Harbor Healthcare SystemManhattan Medical CenterNew YorkUSA
  4. 4.Inflammatory Bowel Disease Center, Division of GastroenterologyNYU Langone HealthNew YorkUSA

Personalised recommendations